Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Technical Presentation (June 2017)

13 slides from Reata Pharmaceuticals's technical presentation, Jun 2, 2017

  1. Slide 1: Safety, Efficacy, and Pharmacodynamics of Omav in Friedreich's Ataxia Patients (MOXIe Part 1 Results)

    Safety, Efficacy, and Pharmacodynamics of Omav (Omaveloxolone) in Friedreich’s Ataxia Patients (MOXIe Trial): Part 1 Results Exhibit 99.3

  2. Slide 2: Summary of MOXIe Part 1 Study Results

    Summary of MOXIe Part 1 Study Results Dose-dependent, placebo-corrected improvements on multiple endpoints including mFARS and peak work The optimal dose of omaveloxolone was identified and demonstrated: Marked activation of Nrf2 Clear improvements in markers of metabolism and mitochondrial function

  3. Slide 3: Overview of Friedreich's Ataxia

    Overview of Friedreich’s Ataxia FA is a progressive and life-shortening neuromuscular disorder Caused by mutations in frataxin Associated with loss of coordination and ambulation, fatigue, and metabolic disturbances No approved treatments Friedreich’s Ataxia Rating Scale (FARS) measures disease seve

  4. Slide 4: Omav Induces Nrf2 and Restores Mitochondrial Function

    Omav Induces Nrf2 and Restores Mitochondrial Function 4 In cultured muscle and FA cells, Omav: Induces Nrf2 as measured by Nrf2 target NQO1 Increases mitochondrial function as measured by ATP levels and transmembrane potential Dose-response shows dose-dependent increases followed by plateau and then

  5. Slide 5: MOXIe Study Design and Patient Disposition

    5 MOXIe Study Design and Patient Disposition MOXIe designed as a two-part study Part 1 designed to assess multiple endpoints across a range of doses Part 2 designed to confirm efficacy and safety Part 1: Phase 2, double-blind, randomized, placebo-controlled, dose-ranging, multi-center, international

  6. Slide 6: Omav Dose-Dependently Increases Nrf2 Targets, Markers of Metabolism and Mitochondrial Function

    Omav Dose-Dependently Increases Nrf2 Targets, Markers of Metabolism and Mitochondrial Function Robust changes in several Nrf2 targets, including ferritin and GGT at 80 – 300 mg Aspartate transaminase (AST) and creatine kinase (CK) are indirectly regulated by Nrf2 and indicative of improved metabolis

  7. Slide 7: Pharmacodynamic Changes Associated with Efficacy Improvements

    Pharmacodynamic Changes Associated with Efficacy Improvements Omav significantly improved mFARS from baseline across all doses (p<0.0001) mFARS changes mirrored AST induction PD and efficacy responses more robust and maximal at doses of 80 – 160 mg Placebo-corrected change at 160 mg (-2.3) neared st

  8. Slide 8: mFARS Change More Robust in Patients without Musculoskeletal Foot Deformity

    mFARS Change More Robust in Patients without Musculoskeletal Foot Deformity Patients who present with FA while growing can develop a musculoskeletal foot deformity that causes high arched feet and is called pes cavus Presence of foot deformity does not affect placebo change in mFARS Placebo-correcte

  9. Slide 9: Peak Work Improved in Patients without Musculoskeletal Foot Deformity

    Peak Work Improved in Patients without Musculoskeletal Foot Deformity Exercise testing did not demonstrate difference between treatment vs. placebo in all patients Received reports from clinical sites that some patients with a foot deformity were unable able to reach peak muscle exhaustion due to fo

  10. Slide 10: Adverse Events

    Adverse Events Adverse events were generally mild in severity Increased upper respiratory tract infections and nasopharyngitis, which were generally mild in severity ALT and AST increases are expected pharmacological effects of Nrf2 activation and were not associated with any signs or symptoms of li

  11. Slide 11: Summary of Part 1 Data

    Summary of Part 1 Data Time-dependent and dose-dependent changes in PD and efficacy assessments most robust at 80 to 160 mg 11 Omav dose (mg)a 5 10 20 40 80 160 300 Number of patients 6 6 6 6 6 12 10 Nrf2 induction in FA patients Ferritin ü ü ü GGT ü ü ü Improved PD markers of metabolism and mitocho

  12. Slide 12: MOXIe Part 2 Study Design

    MOXIe Part 2 Study Design Based on data from dose-ranging portion of trial, have optimized design of confirmatory phase of trial (Part 2) Assessing multiple efficacy endpoints Multiple design elements incorporated to limit variability and improve sensitivity Conservatively powered to detect a smalle

  13. Slide 13: Upcoming Key Events and Timing

    Upcoming Key Events and Timing Bard is currently being developed unilaterally by Reata, and AbbVie retains the right to opt back into development. Reata retains commercial rights in US market; KHK has rights in certain Asian markets; AbbVie has rights in non-KHK markets outside the US. Reata’s next

Reata Pharmaceuticals — Technical Presentation (June 2017) on 6ix